The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates.
There are currently no approved medical radiation countermeasures (MRC) to reduce the lethality of high-dose total body ionizing irradiation expected in nuclear emergencies. An ideal MRC would be effective even when administered well after radiation exposure and would counteract the effects of irrad...
Main Authors: | Vadim I Krivokrysenko, Ilia A Toshkov, Anatoli S Gleiberman, Peter Krasnov, Inna Shyshynova, Ivan Bespalov, Ratan K Maitra, Natalya V Narizhneva, Vijay K Singh, Mark H Whitnall, Andrei A Purmal, Alexander N Shakhov, Andrei V Gudkov, Elena Feinstein |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4569586?pdf=render |
Similar Items
-
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
by: Gary J Haderski, et al.
Published: (2020-01-01) -
A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
by: Vadim Mett, et al.
Published: (2021-04-01) -
Intein-mediated backbone cyclization of entolimod confers enhanced radioprotective activity in mouse models
by: Bingyu Ye, et al.
Published: (2018-06-01) -
A Clinical Trial of Entolimod a TLR-5 Adjuvant for Vaccines Using Diphtheria or Tetanus as Carrier Proteins
by: Thomas R. Kosten, et al.
Published: (2022-09-01) -
Resistance of bone marrow stroma to genotoxic preconditioning is determined by p53
by: Natalia Fedtsova, et al.
Published: (2021-05-01)